Article Figures & Data
Figures
- FIGURE 1.
Contribution of T/M ratio of 18F-FDG in metastatic pulmonary tumors, control group (benign lesion), and NSCLC. T/M ratio was significantly higher in patients with metastatic pulmonary tumors (P = 0.0261) and NSCLC (P < 0.0001) than in control group. T/M ratio of metastatic pulmonary tumors was significantly lower than that of NSCLC (P < 0.0001). PMT = metastatic pulmonary tumor.
- FIGURE 2.
Overall survival curve according to T/M ratio. Overall survival of patients with high T/M ratio was significantly longer than that of patients with low T/M ratio.
Tables
- TABLE 1
Comparison of 18F-FDG Uptake and Biomarkers Between Pulmonary Metastases and Primary Lung Cancer
All cases Adenocarcinoma SQC Biomarker Metastasis (n = 146) Primary (n = 138) P Metastasis (n = 103) Primary (n = 93) P Metastasis (n = 13) Primary (n = 45) P T/M ratio 3.25 ± 0.22 5.96 ± 0.38 <0.0001 3.42 ± 0.27 4.47 ± 0.40 0.0281 3.67 ± 0.78 9.04 ± 0.64 <0.0001 Glut1 2.92 ± 0.08 2.42 ± 0.09 <0.0001 3.12 ± 0.09 2.02 ± 0.09 <0.0001 3.39 ± 0.18 3.23 ± 0.09 0.4716 Glut3 1.27 ± 0.05 1.30 ± 0.06 0.6250 1.12 ± 0.04 1.29 ± 0.07 0.0220 1.46 ± 0.22 1.33 ± 0.10 0.5616 Hexokinase I 2.53 ± 0.09 2.81 ± 0.10 0.0295 2.55 ± 0.09 2.49 ± 0.12 0.6979 3.15 ± 0.32 3.45 ± 0.13 0.3244 HIF-1α 2.90 ± 0.09 3.42 ± 0.11 0.0004 3.02 ± 0.10 2.50 ± 0.12 0.0007 3.69 ± 0.17 4.15 ± 0.15 0.1246 VEGF 23.9 ± 1.50 30.3 ± 1.70 0.0050 24.0 ± 1.70 24.5 ± 1.80 0.8381 41.5 ± 5.10 44.9 ± 2.70 0.5615 CD34 25.1 ± 0.90 24.0 ± 1.10 0.4518 24.4 ± 1.10 20.3 ± 1.30 0.0160 32.9 ± 2.50 31.5 ± 1.30 0.6115 - TABLE 2
Comparison of 18F-FDG Uptake and Biomarkers Between Malignant Lesions and Benign Lesions
Pulmonary metastasis vs. control group Primary lung cancer vs. control group Biomarker Malignant (n = 146) Benign (n = 29) P Malignant (n = 140) Benign (n = 29) P T/M ratio 3.25 ± 0.22 2.12 ± 0.25 0.0261 5.96 ± 0.38 2.12 ± 0.25 <0.0001 Glut1 2.92 ± 0.08 1.83 ± 0.16 <0.0001 2.42 ± 0.09 1.83 ± 0.16 0.0048 Glut3 1.27 ± 0.05 1.76 ± 0.15 0.0003 1.30 ± 0.06 1.76 ± 0.15 0.0012 Hexokinase I 2.53 ± 0.09 1.89 ± 0.15 0.0022 2.81 ± 0.10 1.89 ± 0.15 <0.0001 HIF-1α 2.90 ± 0.09 2.10 ± 0.17 0.0003 3.42 ± 0.11 2.10 ± 0.17 <0.0001 VEGF 23.9 ± 1.50 13.2 ± 2.34 0.0024 30.3 ± 1.70 13.2 ± 2.34 <0.0001 CD34 25.1 ± 0.90 17.8 ± 1.73 0.0019 24.0 ± 1.10 17.8 ± 1.73 0.0125 - TABLE 3
Comparison of 18F-FDG Uptake and Biomarkers Among Patients with Pulmonary Metastases
Adenocarcinoma vs. SQC Adenocarcinoma vs. sarcoma SQC vs. sarcoma Biomarker Adenocarcinoma (n = 103) SQC (n = 13) P Adenocarcinoma(n = 103) Sarcoma (n = 17) P SQC (n = 13) Sarcoma (n = 17) P T/M ratio 3.43 ± 0.27 3.68 ± 0.78 0.7635 3.43 ± 0.27 2.04 ± 0.35 0.0467 3.67 ± 0.78 2.04 ± 0.35 0.0473 Glut1 3.12 ± 0.09 3.39 ± 0.18 0.3012 3.12 ± 0.09 1.82 ± 0.21 <0.0001 3.39 ± 0.18 1.82 ± 0.21 <0.0001 Glut3 1.12 ± 0.04 1.46 ± 0.22 0.0117 1.12 ± 0.04 1.77 ± 0.26 <0.0001 1.46 ± 0.22 1.77 ± 0.26 0.4030 Hexokinase I 2.55 ± 0.09 3.15 ± 0.32 0.0429 2.55 ± 0.09 2.06 ± 0.25 0.6979 3.15 ± 0.32 2.06 ± 0.25 0.0102 HIF-1α 3.02 ± 0.10 3.69 ± 0.17 0.0198 3.02 ± 0.10 1.77 ± 0.24 <0.0001 3.69 ± 0.17 1.77 ± 0.24 <0.0001 VEGF 24.0 ± 1.70 41.5 ± 5.07 0.0009 24.0 ± 1.70 15.7 ± 3.92 0.0482 41.5 ± 5.07 15.7 ± 3.92 0.0003 CD34 24.4 ± 1.14 32.9 ± 2.55 0.0121 24.4 ± 1.14 25.1 ± 2.99 0.8169 32.9 ± 2.55 25.1 ± 2.99 0.0667
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma?
- Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species-Mediated Hypoxia-Inducible Factor-1{alpha} Activation
- Heterogeneity in Intratumor Correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in Canine Sinonasal Tumors
- Multifunctional Profiling of Non-Small Cell Lung Cancer Using 18F-FDG PET/CT and Volume Perfusion CT